Table 1 Significant PharmGKB signaling pathways
From: A weighted accumulation test for associating rare genetic variation with quantitative phenotypes
PharmGKB ID | Pathway name | Permutation p-value (weighted approach) | Permutation p-value (unweighted approach) |
|---|---|---|---|
PA164713582†* | Actions of nitric oxide in the heart | 6.0 × 10–6 | <1.0 × 10–6 |
PA164713652†* | VEGF hypoxia and angiogenesis | <1.0 × 10–6 | 6.0 × 10–6 |
PA164728105†* | Signaling events mediated by VEGFR1 and VEGFR2 | <1.0 × 10–6 | <1.0 × 10–6 |
PA164728138†* | S1P3 pathway | <1.0 × 10–6 | <1.0 × 10–6 |
PA164713890†| Neurophilin interactions with VEGF and VEGFR | <1.0 × 10–6 | 1.7 × 10–5 |
PA164714260†| VEGF binds to VEGFR leading to receptor dimerization | <1.0 × 10–6 | 3.3 × 10–5 |
PA164728144†| VEGFR1-specific signals | <1.0 × 10–6 | 1.70 × 10–4 |
PA164728199†| Integrins in angiogenesis | 9.0 × 10–6 | (a) |
PA164728205†* | S1P1 pathway | 8.0 × 10–6 | 1.1 × 10–5 |
PA164728223†| HIF-1-alpha transcription factor network | <1.0 × 10–6 | 1.92 × 10–4 |
PA164728227†* | Glypican 1 network | 1.0 × 10–6 | <1.0 × 10–6 |
PA2032†* | VEGF pathway | <1.0 × 10–6 | <1.0 × 10–6 |